BioLegend, Inc., a leading manufacturer and supplier of antibodies and reagents that covers a diverse set of research areas including immunology, cancer research, neuroscience, proteogenomics, stem cells, and other emerging sectors, has signed an exclusive distribution agreement with Alliance Global (AGBL) Group.
“BioLegend is continually expanding its product offerings globally. AGBL is an important new strategic partner in emerging markets”, stated Craig Monell, Senior VP, Business Operations at BioLegend.
AGBL Sales Director, Fady Al Assaly, expressed his contentment with this “We are always seeking to bring the best products and service to our customers, we believe that BioLegend products will complement our range of cell biology and flow cytometry range of products and will enrich our offering to our customers in the region.”
-Ends-
About BioLegend
BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we have secured loyal customers and trusted partners at the world’s premier research institutions, biotechnology and pharmaceutical companies. BioLegend scientists collaboratively develop cutting-edge research and diagnostic products, transforming the boundaries of innovation for basic science and medical researchers worldwide.
About Alliance Global
Alliance Global is a member of the AGBL group of companies, the largest biomedical distribution group in the Middle East, Africa, and Asia region. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centers in emerging healthcare markets. www.agbl.net
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
